HBV Infection and Chronic Hepatitis B
Hepatitis B virus (HBV) is a hepatotropic virus and one of the leading causes by both persistent and chronic infection of hepatitis B in human globally, more over China is a high population was affected by HBV. Currently ETV, TDF, and INF are recommended as a first-line treatment; however, many HBV positive patients will progress to a late stage with diseases such as, chronic hepatitis B cirrhosis and hepatocellular carcinoma (HCC). The uses of pegylated interferon-alpha for 48 weeks have led to a long-term control of HBV, but occasionally treatment failure is observed in a maximum no of patients. Prolonged use of NAs has proofed to suppress the virus, though safety and efficacy is not yet clarified, NAs unable clear the virus from infected cells, suggesting that the disease progression may not be stopped and the risk of development of significant complications is not yet eliminated. Novel treatment strategies are required.